268 related articles for article (PubMed ID: 32965680)
41. Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma.
Muta T; Miyamoto T; Fujisaki T; Ohno Y; Kamimura T; Kato K; Takenaka K; Iwasaki H; Eto T; Takamatsu Y; Teshima T; Akashi K;
Intern Med; 2013; 52(1):63-70. PubMed ID: 23291675
[TBL] [Abstract][Full Text] [Related]
42. Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience.
Katragadda L; McCullough LM; Dai Y; Hsu J; Byrne M; Hiemenz J; May S; Cogle CR; Norkin M; Brown RA; Wingard JR; Chang M; Moreb JS
Clin Transplant; 2016 Aug; 30(8):894-900. PubMed ID: 27219740
[TBL] [Abstract][Full Text] [Related]
43. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
[TBL] [Abstract][Full Text] [Related]
44. Final outcomes of escalated melphalan 280 mg/m
Hari P; Reece DE; Randhawa J; Flomenberg N; Howard DS; Badros AZ; Rapoport AP; Meisenberg BR; Filicko-Ohara J; Phillips GL; Vesole DH
Bone Marrow Transplant; 2019 Feb; 54(2):293-299. PubMed ID: 29907806
[TBL] [Abstract][Full Text] [Related]
45. Early infectious complications after autologous hematopoietic cell transplantation for multiple myeloma.
Rahman S; Rybicki L; Ky Hamilton B; Pohlman B; Jagadeesh D; Cober E; Kalaycio M; Dean R; Sobecks R; Mossad SB; Majhail NS
Transpl Infect Dis; 2019 Aug; 21(4):e13114. PubMed ID: 31102556
[TBL] [Abstract][Full Text] [Related]
46. Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study.
Ghilardi G; Pabst T; Jeker B; Müller R; Cairoli A; Müller AMS; Bargetzi M; Hitz F; Baldomero H; Heim D; Schmidt A; Rossi D; Ghielmini M; Wannesson L; Lerch E; Samaras P; Schanz U; Passweg JR; Stussi G; Kleber M; Gerber B;
Bone Marrow Transplant; 2019 Jul; 54(7):1029-1037. PubMed ID: 30390061
[TBL] [Abstract][Full Text] [Related]
47. Comparison of Patient Outcomes With Two Different Formulations of Melphalan as Conditioning Chemotherapy for Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.
Khan AM; Yucebay F; Zhao Q; Umyarova E; Cottini F; Bumma N; Rosko A; Benson D; Sharma N; Efebera Y; Devarakonda S
Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):e85-e96. PubMed ID: 36411211
[TBL] [Abstract][Full Text] [Related]
48. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
[TBL] [Abstract][Full Text] [Related]
49. Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma.
Parrish C; Rahemtulla A; Cavet J; Pearce RM; Kirkland K; Lee J; Cook M; Wilson K; Cook G;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1330-4. PubMed ID: 25843652
[TBL] [Abstract][Full Text] [Related]
50. Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation.
Chan H; Phillips M; Maganti M; Farooki S; Piza Rodriguez G; Masih-Khan E; Chen C; Prica A; Reece D; Tiedemann R; Trudel S; Kukreti V
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):225-234. PubMed ID: 29397346
[TBL] [Abstract][Full Text] [Related]
51. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
[TBL] [Abstract][Full Text] [Related]
52. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.
Kumar A; Kharfan-Dabaja MA; Glasmacher A; Djulbegovic B
J Natl Cancer Inst; 2009 Jan; 101(2):100-6. PubMed ID: 19141779
[TBL] [Abstract][Full Text] [Related]
53. Autologous transplantation and maintenance therapy in multiple myeloma.
Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics and Efficacy of Generic Melphalan Is Comparable to Innovator Formulation in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Pai AA; Devasia AJ; Panetta JC; Mani S; Stallon Illangeswaran RS; Mohanan E; Balakrishnan B; Lakshmi KM; Kulkarni U; Aboobacker FN; Korula A; Abraham A; Srivastava A; Mathews V; George B; Balasubramanian P
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):130-135.e1. PubMed ID: 31791694
[TBL] [Abstract][Full Text] [Related]
55. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
56. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial.
Vesole DH; Crowley JJ; Catchatourian R; Stiff PJ; Johnson DB; Cromer J; Salmon SE; Barlogie B
J Clin Oncol; 1999 Jul; 17(7):2173-9. PubMed ID: 10561273
[TBL] [Abstract][Full Text] [Related]
57. Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation.
Cheng YC; Shi Y; Zhang MJ; Brazauskas R; Hemmer MT; Bishop MR; Nieto Y; Stadtmauer E; Ayash L; Gale RP; Lazarus H; Holmberg L; Lill M; Olsson RF; Wirk BM; Arora M; Hari P; Ueno N
J Cancer; 2017; 8(6):1009-1017. PubMed ID: 28529613
[No Abstract] [Full Text] [Related]
58. A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents.
Su B; Zhu X; Jiang Y; Wang L; Zhao N; Ran X; Zheng X; Guo H
Leuk Lymphoma; 2019 Jun; 60(6):1381-1388. PubMed ID: 30516074
[TBL] [Abstract][Full Text] [Related]
59. A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97.
Vesole DH; Zhang L; Flomenberg N; Greipp PR; Lazarus HM; Huff CA;
Biol Blood Marrow Transplant; 2009 Jan; 15(1):83-91. PubMed ID: 19135946
[TBL] [Abstract][Full Text] [Related]
60. Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial.
Giralt S; Costa LJ; Maloney D; Krishnan A; Fei M; Antin JH; Brunstein C; Geller N; Goodman S; Hari P; Logan B; Lowsky R; Qazilbash MH; Sahebi F; Somlo G; Rowley S; Vogl DT; Vesole DH; Pasquini M; Stadtmauer E
Biol Blood Marrow Transplant; 2020 Apr; 26(4):798-804. PubMed ID: 31756536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
